All In Biotech

NDA 213400 · Epizyme INC

Tazverik

Tazemetostat Hydrobromide · Oral

Accelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jun 18, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 18, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

0 Phase 3, 0 recruiting

FAERS reports

1,622

721 serious, 216 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 18, 2020 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · priority review Accelerated approvalOrphanLabelMedication GuideLetter
1 products under this application
  • TAZVERIK · TAZEMETOSTAT HYDROBROMIDE 200MG · TABLET, ORAL · Prescription · TE TBD

Clinical trials

Interventional ClinicalTrials.gov studies with "Tazemetostat Hydrobromide" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use335
  • fatigue326
  • disease progression305
  • nausea235
  • product dose omission issue212
  • death132
  • diarrhoea123
  • decreased appetite97
  • vomiting95
  • asthenia83
  • constipation80
  • headache74

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20173
201811
20196
202081
2021256
2022395
2023316
2024205
2025242
2026107

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tazverik (Tazemetostat Hydrobromide)

2024 spending

$25.1M

Beneficiaries

228

1,417 claims

Per beneficiary

$110,237

$81.67 per unit

View as table
YearSpending
2020$2,816,560
2021$8,150,727
2022$14,801,232
2023$18,985,929
2024$25,134,062

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Epizyme INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.